

PT-141 / Bremelanotide

PRODUCT DESCRIPTION

Bremelanotide (PT-141) selectively activates MC3R/MC4R in the hypothalamus to modulate sexual desire via central dopaminergic stimulation. FDA-approved as Vyleesi® for hypoactive sexual desire disorder (HSDD) in premenopausal women. First centrally acting melanocortin-based sexual dysfunction therapeutic.

PRODUCT SPECIFICATIONS

Catalog Number	BPT2920
CAS Number	189691-06-3
Molecular Weight	1025.18 Da
Molecular Formula	C50H68N14O10
Purity	Peak Area by HPLC >=95%
Form	Lyophilized
Source	Synthetic (Chemical Synthesis, SPPS)
Endotoxin	N/A (Synthetic peptide)

AMINO ACID SEQUENCE

One-Letter Code:

Ac-Nle-c[Asp-His-D-Phe-Arg-Trp-Lys]-OH (cyclic)

Three-Letter Code:

Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH

RESEARCH APPLICATIONS

Application	Receptor binding
Biomarker Target	Melanocortin Receptors (MC1-5R)
Research Area	Endocrinology
Sub-category	Melanocortin System & Pigmentation

STORAGE & HANDLING

Storage Temperature	-20 deg C
Form	Lyophilized
Stability	Lyophilized product stable for 24 months at -20 deg C
Reconstitution	Reconstitute in sterile water or appropriate buffer
After Reconstitution	Aliquot and store at -20 to -80 deg C
Avoid	Repeated freeze-thaw cycles

AVAILABLE SIZES

Size Options	1 mg, 10 mg
Usage	Research use

QUALITY CONTROL

Purity Method	HPLC, Mass Spectrometry (MS)
Identity	Confirmed by ESI-MS or MALDI-TOF
Purity	Peak Area by HPLC >=95%
Documentation	Certificate of Analysis (CoA) available upon request